FDA approves Tibsovo for IDH1-mutated cholangiocarcinoma

FDA approves Tibsovo for IDH1-mutated cholangiocarcinoma

The FDA approved ivosidenib tablets for adults with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma.Cholangiocarcinoma is an aggressive cancer of the bile ducts. An estimated 8,000 people in the United States are diagnosed with cholangiocarcinoma each year, and up to 20% of patients with cholangiocarcinoma harbor IDH1 mutations.Ivosidenib tablets (Tibsovo, Servier Pharmaceuticals) is an isocitrate dehydrogenase-1 (IDH1) inhibitor approved in the United States for treatment of certain patients with acute myeloid leukemia.Servier submitted a supplemental newRead More

Share on facebook
Share on twitter
Share on linkedin